ranolazine

Generic: ranolazine

Labeler: a2a integrated pharmaceuticals
NDC Directory HUMAN PRESCRIPTION DRUG ANDA Inactive Finished

Drug Facts

Product Profile

Brand Name ranolazine
Generic Name ranolazine
Labeler a2a integrated pharmaceuticals
Dosage Form TABLET, FILM COATED, EXTENDED RELEASE
Routes
ORAL
Active Ingredients

ranolazine 1000 mg/1

Manufacturer
A2A Integrated Pharmaceuticals

Identifiers & Regulatory

Product NDC 73141-022
Product ID 73141-022_32becc54-372f-b7eb-e063-6294a90a48b0
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category ANDA
Application Number ANDA213517
Listing Expiration 2026-12-31
Marketing Start 2025-04-08

Pharmacologic Class

Established (EPC)
anti-anginal [epc]
Mechanism of Action
cytochrome p450 3a inhibitors [moa] p-glycoprotein inhibitors [moa] cytochrome p450 2d6 inhibitors [moa] organic cation transporter 2 inhibitors [moa]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 73141022
Hyphenated Format 73141-022

Supplemental Identifiers

RxCUI
616749 728231
UPC
0373141021020 0373141022027
UNII
A6IEZ5M406
NUI
N0000175427 N0000190114 N0000185503 N0000182137 N0000187061

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name ranolazine (source: ndc)
Generic Name ranolazine (source: ndc)
Application Number ANDA213517 (source: ndc)
Routes
ORAL
source: ndc

Resolved Composition

Strengths
  • 1000 mg/1
source: ndc
Packaging
  • 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (73141-022-02)
source: ndc

Packages (1)

73141-022-02 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (73141-022-02)

Ingredients (1)

ranolazine (1000 mg/1)

Linked Drug Pages (1)

RANOLAZINE ndc-match (0.9)

Raw FDA Data

View complete raw FDA NDC JSON payload 
{"route": ["ORAL"], "spl_id": "32becc54-372f-b7eb-e063-6294a90a48b0", "openfda": {"nui": ["N0000175427", "N0000190114", "N0000185503", "N0000182137", "N0000187061"], "upc": ["0373141021020", "0373141022027"], "unii": ["A6IEZ5M406"], "rxcui": ["616749", "728231"], "spl_set_id": ["9fb62878-c76a-4be2-99be-962ce2956af2"], "pharm_class_epc": ["Anti-anginal [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Organic Cation Transporter 2 Inhibitors [MoA]"], "manufacturer_name": ["A2A Integrated Pharmaceuticals"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (73141-022-02)", "package_ndc": "73141-022-02", "marketing_start_date": "20250408"}], "brand_name": "RANOLAZINE", "product_id": "73141-022_32becc54-372f-b7eb-e063-6294a90a48b0", "dosage_form": "TABLET, FILM COATED, EXTENDED RELEASE", "pharm_class": ["Anti-anginal [EPC]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "Organic Cation Transporter 2 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "product_ndc": "73141-022", "generic_name": "RANOLAZINE", "labeler_name": "A2A Integrated Pharmaceuticals", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "RANOLAZINE", "active_ingredients": [{"name": "RANOLAZINE", "strength": "1000 mg/1"}], "application_number": "ANDA213517", "marketing_category": "ANDA", "marketing_start_date": "20250408", "listing_expiration_date": "20261231"}